Launch week offerEnds in00h00m00s
annual Promonthly Pro
Victoria Leiro
Has grant
Research Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Contracted Researcher
Open Date: 2017-06-01
Close Date:
Grant: Close
Post-doctoral Fellow
Open Date: 2011-04-01
Close Date: 2014-03-01
Grant: Close
Formación de Profesorado Universitario (FPU)
Open Date: 2003-03-01
Close Date: 2007-02-01
Grant: Close
Premio de Licenciatura
Open Date: 2003-01-01
Close Date: 2023-01-01
Grant: Close
Premio Extraordinario de Licenciatura en Química 2002/2003
Open Date: 2003-01-01
Close Date: 2003-01-01
Articles (4)
Year:
2025
Year:
2024
Year:
2023
Alzheimer’s disease (AD) is the most prevalent form of dementia. It affects more than 30 million people worldwide and costs over US$ 1.3 trillion annually. AD is characterized by the brain accumulation of amyloid β peptide in fibrillar structures and the accumulation of hyperphosphorylated tau aggregates in neurons, both leading to toxicity and neuronal death. At present, there are only seven drugs approved for the treatment of AD, of which only two can slow down cognitive decline. Moreover, their use is only recommended for the early stages of AD, meaning that the major portion of AD patients still have no disease-modifying treatment options. Therefore, there is an urgent need to develop efficient therapies for AD. In this context, nanobiomaterials, and dendrimers in particular, offer the possibility of developing multifunctional and multitargeted therapies. Due to their intrinsic characteristics, dendrimers are first-in-class macromolecules for drug delivery. They have a globular, well-defined, and hyperbranched structure, controllable nanosize and multivalency, which allows them to act as efficient and versatile nanocarriers of different therapeutic molecules. In addition, different types of dendrimers display antioxidant, anti-inflammatory, anti-bacterial, anti-viral, anti-prion, and most importantly for the AD field, anti-amyloidogenic properties. Therefore, dendrimers can not only be excellent nanocarriers, but also be used as drugs per se. Here, the outstanding properties of dendrimers and derivatives that make them excellent AD nanotherapeutics are reviewed and critically discussed. The biological properties of several dendritic structures (dendrimers, derivatives, and dendrimer-like polymers) that enable them to be used as drugs for AD treatment will be pointed out and the chemical and structural characteristics behind those properties will be analysed. The reported use of these nanomaterials as nanocarriers in AD preclinical research is also presented. Finally, future perspectives and challenges that need to be overcome to make their use in the clinic a reality are discussed.
Year:
2023
Collaborators (8)
Eran Perlson
Academic, Head, Department Chair Faculty of Medical & Health Science
Tel Aviv University
M. Cristina Martins
Invited Assistant Professor
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar
Raquel Goncalves
Affiliated Professor
Instituto de Ciências Biomédicas Abel Salazar
Ben M. Maoz
Tel Aviv University
Paula Parreira
Associate Researcher
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto
Jose Bessa
Group Leader of the research group "Vertebrate Development and Regeneration"
Instituto de Investigação e Inovação em Saúde da Universidade do Porto
Débora Moreira
Junior Investigator
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto
Ana P. Pêgo
Principal Investigator
University of Porto
Make your next move.
Prepare your application
Review drafts before you send them.